Table 2.

DEBIRI treatments and hepatic lesion characteristics

Variables	n (%)
Doses of DEBIRI (median 100 mg)
100 mg	26/44 (59) treatments
200 mg	18/44 (41) treatments
Sites of treatments
Right liver	36/44 (81.8) treatments
Left liver	6/44 (13.6) treatments
Whole liver	2/44 (4.6) treatments
Number of hepatic lesions for treatment	Median: 3; range: 1–20
Hepatic lesions size	Mean: 31.86 mm; range: 8–115 mm
Total target lesion size (sum of a maximum of 5 lesions)	88 mm; range: 10–240 mm

Abbreviation: DEBIRI, drug-eluting beads with irinotecan.